Evidence map›Paper›PMID 38221792›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2024

Identification and evaluation of antiviral activity of novel compounds targeting SARS-CoV-2 virus by enzymatic and antiviral assays, and computational analysis.

Ivana Nemčovičová, Katarína Lopušná, Iveta Štibrániová, Fabio Benedetti, Federico Berti, Fulvia Felluga, Sara Drioli, Mattia Vidali, Jaroslav Katrlík, Lucia Pažitná and 13 more

Abstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Ivana NemčovičováBiomedical Research Center, Institute of Virology, Slovak Academy of Sciences, Bratislava, Slovakia.
Katarína LopušnáBiomedical Research Center, Institute of Virology, Slovak Academy of Sciences, Bratislava, Slovakia.
Iveta ŠtibrániováBiomedical Research Center, Institute of Virology, Slovak Academy of Sciences, Bratislava, Slovakia.
Fabio BenedettiDepartment of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste, Italy.
Federico BertiDepartment of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste, Italy.
Fulvia FellugaDepartment of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste, Italy.
Sara DrioliDepartment of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste, Italy.
Mattia VidaliDepartment of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste, Italy.
Jaroslav KatrlíkInstitute of Chemistry, Slovak Academy of Sciences, Bratislava, Slovakia.
Lucia PažitnáInstitute of Chemistry, Slovak Academy of Sciences, Bratislava, Slovakia.
Alena HolazováInstitute of Chemistry, Slovak Academy of Sciences, Bratislava, Slovakia.
Jana BlahutováInstitute of Chemistry, Slovak Academy of Sciences, Bratislava, Slovakia.
Simona LenhartováBiomedical Research Center, Institute of Virology, Slovak Academy of Sciences, Bratislava, Slovakia.
Monika SlávikováBiomedical Research Center, Institute of Virology, Slovak Academy of Sciences, Bratislava, Slovakia.
Boris KlempaBiomedical Research Center, Institute of Virology, Slovak Academy of Sciences, Bratislava, Slovakia.
Miroslav OndrejovičDepartment of Biotechnology, Faculty of Natural Sciences, University of Ss. Cyril and Methodius in Trnava, Trnava, Slovakia.
Daniela ChmelováDepartment of Biotechnology, Faculty of Natural Sciences, University of Ss. Cyril and Methodius in Trnava, Trnava, Slovakia.
Barbora LegerskáDepartment of Biotechnology, Faculty of Natural Sciences, University of Ss. Cyril and Methodius in Trnava, Trnava, Slovakia.
Stanislav MiertušDepartment of Biotechnology, Faculty of Natural Sciences, University of Ss. Cyril and Methodius in Trnava, Trnava, Slovakia.
Mária KlacsováDepartment of Physical Chemistry of Drugs, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovakia.
Daniela UhríkováDepartment of Physical Chemistry of Drugs, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovakia.
Lukáš KertiDepartment of Physical Chemistry of Drugs, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovakia.
Vladimír FrecerDepartment of Physical Chemistry of Drugs, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovakia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The viral genome of the SARS-CoV-2 coronavirus, the aetiologic agent of COVID-19, encodes structural, non-structural, and accessory proteins. Most of these components undergo rapid genetic variations, though to a lesser extent the essential viral proteases. Consequently, the protease and/or deubiquitinase activities of the cysteine proteases M

Indexed as

COVID-19Cysteine ProteasesAntiviral AgentsCysteine EndopeptidasesHumansMolecular Docking SimulationProtease InhibitorsSARS-CoV-2Viral Nonstructural ProteinsAntiviral AgentsCysteine EndopeptidasesCysteine ProteasesProtease InhibitorsViral Nonstructural Proteinsbis(benzylidene)cyclohexanone inhibitorsenzyme inhibition assaysin vitro antiviral effectSARS-CoV-2 viral cysteine proteases Mpro and PLpro

Identifiers

PMID38221792
PMCPMC10791089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.